摘要
目的观察依达拉奉联合奥扎格雷钠治疗进展性脑梗死(PCI)的疗效和安全性。方法选择发病在48h内的PCI患者94例,随机分成治疗组(48例)和对照组(46例)。治疗组给予奥扎格雷钠80mg+生理盐水100ml,bid,同时给予依达拉奉30mg加入生理盐水100ml静滴,bid,连用14d;对照组仅用同剂量、同疗程的奥扎格雷钠。依据神经功能缺损程度评分标准(NDS)评分,日常生活能力(Barthel指数,BI)评分评定神经功能缺损程度,并监测肝肾功能、血尿常规及心电图。结果治疗组与对照组相比,NDS评分在治疗后1周差异有显著性(P<0.05),治疗后2周时差异更显著(P<0.01),而BI评分在治疗后1周和2周时差异有显著性(P<0.05),治疗后3周时差异更显著(P<0.01)。2组均未见明显不良反应。结论奥扎格雷钠和依达拉奉联合治疗PCI患者疗效较好,安全性好。
Objective To investigate the efficacy and safety of Edaravone combined Ozagrel sodium for patients with progressive cerebral infarction（PCI）. Methods Ninety-four PCI patients within 48 hours of onset were enrolled. They were randomly divided into treatment group（48 cases）and control group（46 cases）. Treatment group was allocated Ozagrel sodium 80rag, bid, for 14 days and Edaravone 30mg,bid,for 14 days. Control group was only allocated Ozagrel sodium 80mg,bid,for 14 days. Therapeutic effect was evaluated by clinical neurological function deficit scale（NDS） and Bathal index（BI）. The liver and renal function, blood and urinary routine, and electrocardiogram（ECG）were detected. Results Compared with control group, there were significant differences after one week（P〈0. 05）and after two weeks （P〈0. 01）in the grades of NDS of treatment group, and there were significant differences after one week or two weeks（P〈0. 05）and after three weeks（P〈0. 01）in the grades of BI of treatment group. There was no side effect in both groups. Conclusion Edaravone combined Ozagrel sodium is an effective and safe therapy for PCI patients.
出处
《中国实用神经疾病杂志》
2008年第11期9-11,共3页
Chinese Journal of Practical Nervous Diseases
关键词
脑梗死
依达拉奉
奥扎格雷钠
Progressive cerebral infarction
Edaravone
Ozagrel sodium
